Who Buys Regorafenib from India — 73 Importers Behind a $1.0M Market

The importers of Regorafenib from India can be categorized into several segments:

1. Distributors: Entities like STR International Trading Co., Ltd and its variants in Thailand, as well as BZ Compnat Limited, likely function as distributors. They procure Regorafenib in bulk to supply to local healthcare providers, pharmacies, or other intermediaries. Their purchasing patterns typically involve large, periodic orders aligned with market demand forecasts.

2. Re-exporters: Companies such as ZMC Express Cargo FZCO in Iraq and Vanterpool Enterprises Ltd in the British Virgin Islands may act as re-exporters. They import pharmaceuticals to redistribute them to other markets, often leveraging favorable trade agreements or logistical advantages. Their buying behavior is characterized by variable order sizes, influenced by the demands of their target export destinations.

3. Government Procurement Agencies: Entities like Client Code PH001 in the Philippines might represent government procurement bodies or agencies involved in national tenders. These organizations typically engage in bulk purchasing through formal tender processes to supply public healthcare facilities. Their procurement cycles are often annual or bi-annual, depending on budget allocations and healthcare program requirements.

4. Hospital Groups and Retail Chains: While specific hospital groups or retail chains are not explicitly identified among the top buyers, it's plausible that some importers serve these segments. These buyers usually place consistent, moderate-sized orders to maintain adequate stock levels for patient care, with purchasing patterns reflecting treatment protocols and patient inflow.

The repeat buyer rate of 38.4% indicates a moderate level of recurring demand, suggesting that while some buyers maintain ongoing procurement relationships, a significant portion of the market consists of one-time or sporadic purchasers.

Understanding the import regulations for Regorafenib in the top importing countries is crucial for market entry and compliance.

The demand for Regorafenib in importing countries is influenced by several factors:

1. Disease Prevalence: Regorafenib is primarily used in the treatment of metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma. The prevalence of these cancers in importing countries directly impacts demand. For instance, according to the World Health Organization (WHO), colorectal cancer is among the top five cancers in France, contributing to significant demand for effective treatments like Regorafenib.

2. Government Healthcare Programs: Many countries have national healthcare programs that subsidize or fully cover the cost of essential medicines. In Thailand, the Universal Coverage Scheme provides access to necessary medications for its citizens, potentially increasing the demand for Regorafenib.

3. Universal Health Coverage Expansion: Countries expanding their universal health coverage are likely to see increased demand for essential medicines. Kenya's efforts to achieve universal health coverage by 2022 have included initiatives to improve access to cancer treatments, which may drive demand for Regorafenib.

4. WHO Essential Medicines List Procurement: Inclusion of a drug in the WHO Essential Medicines List (EML) can influence its procurement by countries aiming to align with WHO recommendations. While Regorafenib is not currently listed in the WHO EML, its recognition as a critical cancer treatment may prompt countries to include it in their national EMLs, thereby increasing demand.

5. Tender-Based Purchasing: Government and large healthcare institutions often procure medicines through tender processes to ensure cost-effectiveness and supply security. The presence of 73 buyers across 37 countries, as per our data, indicates a competitive market where tender-based purchasing is a common practice, influencing the demand dynamics for Regorafenib.

In summary, the demand for Regorafenib is driven by disease prevalence, government healthcare initiatives, efforts towards universal health coverage, alignment with WHO recommendations, and procurement practices. These factors collectively present a substantial market opportunity for Regorafenib in the analyzed importing countries.

The importers of Regorafenib from India can be categorized into several segments:

1. Distributors: Entities like STR International Trading Co., Ltd and its variants in Thailand, as well as BZ Compnat Limited, likely function as distributors. They procure Regorafenib in bulk to supply to local healthcare providers, pharmacies, or other intermediaries. Their purchasing patterns typically involve large, periodic orders aligned with market demand forecasts.

2. Re-exporters: Companies such as ZMC Express Cargo FZCO in Iraq and Vanterpool Enterprises Ltd in the British Virgin Islands may act as re-exporters. They import pharmaceuticals to redistribute them to other markets, often leveraging favorable trade agreements or logistical advantages. Their buying behavior is characterized by variable order sizes, influenced by the demands of their target export destinations.

3. Government Procurement Agencies: Entities like Client Code PH001 in the Philippines might represent government procurement bodies or agencies involved in national tenders. These organizations typically engage in bulk purchasing through formal tender processes to supply public healthcare facilities. Their procurement cycles are often annual or bi-annual, depending on budget allocations and healthcare program requirements.

4. Hospital Groups and Retail Chains: While specific hospital groups or retail chains are not explicitly identified among the top buyers, it's plausible that some importers serve these segments. These buyers usually place consistent, moderate-sized orders to maintain adequate stock levels for patient care, with purchasing patterns reflecting treatment protocols and patient inflow.

The repeat buyer rate of 38.4% indicates a moderate level of recurring demand, suggesting that while some buyers maintain ongoing procurement relationships, a significant portion of the market consists of one-time or sporadic purchasers.

Understanding the import regulations for Regorafenib in the top importing countries is crucial for market entry and compliance.

The demand for Regorafenib in importing countries is influenced by several factors:

1. Disease Prevalence: Regorafenib is primarily used in the treatment of metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma. The prevalence of these cancers in importing countries directly impacts demand. For instance, according to the World Health Organization (WHO), colorectal cancer is among the top five cancers in France, contributing to significant demand for effective treatments like Regorafenib.

2. Government Healthcare Programs: Many countries have national healthcare programs that subsidize or fully cover the cost of essential medicines. In Thailand, the Universal Coverage Scheme provides access to necessary medications for its citizens, potentially increasing the demand for Regorafenib.

3. Universal Health Coverage Expansion: Countries expanding their universal health coverage are likely to see increased demand for essential medicines. Kenya's efforts to achieve universal health coverage by 2022 have included initiatives to improve access to cancer treatments, which may drive demand for Regorafenib.

4. WHO Essential Medicines List Procurement: Inclusion of a drug in the WHO Essential Medicines List (EML) can influence its procurement by countries aiming to align with WHO recommendations. While Regorafenib is not currently listed in the WHO EML, its recognition as a critical cancer treatment may prompt countries to include it in their national EMLs, thereby increasing demand.

5. Tender-Based Purchasing: Government and large healthcare institutions often procure medicines through tender processes to ensure cost-effectiveness and supply security. The presence of 73 buyers across 37 countries, as per our data, indicates a competitive market where tender-based purchasing is a common practice, influencing the demand dynamics for Regorafenib.

In summary, the demand for Regorafenib is driven by disease prevalence, government healthcare initiatives, efforts towards universal health coverage, alignment with WHO recommendations, and procurement practices. These factors collectively present a substantial market opportunity for Regorafenib in the analyzed importing countries.